BIO & Beyond Ep. 3 | CirCode Biomed's Chenxiang Tang on China's Path to True RNA Innovation

«Growing from generic products to fast followers, all the way to true innovation. I think the past 30 to 40 years laid a very good foundation». Episode 3 of our interview series, filmed at BIO 2026. We sit down with Chenxiang Tang, CEO of CirCode Biomed and a structural biologist by training (Tsinghua University, PhD from Yale). Since joining CirCode at the end of 2021, he has taken the company from discovering circular RNA's coding function to becoming the only circRNA player holding regulatory approvals from both the US and China, with pivotal trials now under way on the mainland. In this conversation, Tang discusses what has really driven China's shift from fast follower to genuine innovator, why the ICH agreement and deepening capital markets in Hong Kong and Shanghai are accelerating that shift, the real tension in taking a China-born platform global, and why he believes the future is bright for the industry. 𝗔𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗦𝗲𝗿𝗶𝗲𝘀 𝗕𝗜𝗢 & 𝗕𝗲𝘆𝗼𝗻𝗱: 𝗖𝗵𝗶𝗻𝗮 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗚𝗼𝗲𝘀 𝗚𝗹𝗼𝗯𝗮𝗹 asks one question across the whole industry: What will it take for China’s innovation to compete globally? Hear answers from the founders building the science, global buyers setting the bar, enabling partners, and the investors underwriting the shift. #BiopharmaChina #circRNA #BIO2026 #RNATherapeutics